ASTEC LIFESCIENCES LIMITED - 533138 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund ASTEC LIFESCIENCES LIMITED - 533138 - Voting Results Of The 29Th Annual General Meeting Held On July 27, 2023 Pursuant To Regulation 44(3)
Please find enclosed the Results of voting pursuant to Regulation 44(3) of SEBI Listing Regulation, 2015. ASTEC LIFESCIENCES LIMITED - 533138 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Schedule III and Regulation 47 of the SEBI Listing Regulations, 2015, please find attached the enclosed copies of the newspaper publications for the Unaudited Financial Results for the Quarter ended June 30, 2023. ASTEC LIFESCIENCES LIMITED - 533138 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Please find attached the proceedings of the 29th Annual General Meeting ("29th AGM") along with the copy of the Scrutinizer''s Report and the Annual Report adopted by the Shareholders of the Company. ASTEC LIFESCIENCES LIMITED - 533138 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Please find attached outcome of 29th Annual General Meeting ("29th AGM") held on Thursday, 27th July, 2023 along with the copy of the Scrutinizer''s Report and Annual Report adopted by the Shareholders of the Company. Q1FY24 Quarterly Result Announced for Astec Lifesciences Ltd.
Agrochemicals company Astec Lifesciences announced Q1FY24 results: Consolidated total income of Rs 144.6 crore in Q1FY24 as compared to Rs 187.0 crore in Q1FY23 Consolidated EBITDA of Rs 4.8 crore in Q1FY24 as compared to Rs 28.2 crore in Q1FY23 Commenting on the performance, N B Godrej, Chairman, Astec LifeSciences, said: "Astec continued to face supply glut in its enterprise products portfolio in both domestic as well as global markets. Muted volumes coupled with pricing headwinds and high costs inventories adversely impacted topline and profitability in Q1FY24. Contract manufacturing (CMO) segment performance, however, was in line with our expectations. Revenues from CMO grew by 3.0x YoY led by new product development while profitability also improved." Result PDF ASTEC LIFESCIENCES LIMITED - 533138 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We have enclosed the copy of the Press Release / Media Release and the same is being placed on the website of the Company. ASTEC LIFESCIENCES LIMITED - 533138 - Board Meeting Outcome for Outcome Of Board Meeting Held On July 27, 2023
Kindy find enclosed the Outcome of the Board Meeting held by the Astec LifeSciences Limited on July 27, 2023. ASTEC LIFESCIENCES LIMITED - 533138 - Outcome Of The Board Meeting Held On 27Th July, 2023
Pursuant to Regulation 30, 33 and 52(4) of the SEBI Listing Regulations, this is to inform you that the Board of Directors of Company at its Meeting held today, i.e. July 27, 2023 has approved the Unaudited Financial Results along with the noting of the Limited Review Report of the Statutory Auditor. ASTEC LIFESCIENCES LIMITED - 533138 - Board Meeting Intimation for Intimation Of Board Meeting As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2023 ,inter alia, to consider and approve Notice is hereby given pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), that the Meeting of the Board of Directors of Astec LifeSciences Limited ('the Company') is scheduled to be held on Thursday, 27th July, 2023, to, inter alia, consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2023 after these results are reviewed by the Audit Committee.